Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jae Min | - |
dc.contributor.author | Lee, Hong Sik | - |
dc.contributor.author | Hyun, Jong Jin | - |
dc.contributor.author | Choi, Hyuk Soon | - |
dc.contributor.author | Kim, Eun Sun | - |
dc.contributor.author | Keum, Bora | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Jeen, Yoon Tae | - |
dc.contributor.author | Chun, Hoon Jai | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Kim, Chang Duck | - |
dc.date.accessioned | 2021-09-03T21:55:29Z | - |
dc.date.available | 2021-09-03T21:55:29Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-07-15 | - |
dc.identifier.issn | 1948-5204 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88059 | - |
dc.description.abstract | AIM: To evaluate the value of systemic inflammation-based markers as prognostic factors for advanced pancreatic cancer (PC). METHODS: Data from 82 patients who underwent combination chemotherapy with gemcitabine and erlotinib for PC from 2011 to 2014 were collected retrospectively. Data that included the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio, and the C-reactive protein (CRP)-to-albumin (CRP/Alb) ratio were analyzed. Kaplan-Meier curves, and univariate and multivariate Cox proportional hazards regression analyses were used to identify the prognostic factors associated with progression-free survival (PFS) and overall survival (OS). RESULTS: The univariate analysis demonstrated the prognostic value of the NLR (P = 0.049) and the CRP/Alb ratio (P = 0.047) in relation to PFS, and a positive relationship between an increase in inflammation-based markers and a poor prognosis in relation to OS. The multivariate analysis determined that an increased NLR (hazard ratio = 2.76, 95% CI: 1.33-5.75, P = 0.007) is an independent prognostic factor for poor OS. There was no association between the PLR and the patients' prognoses in those who had received chemotherapy that comprised gemcitabine and erlotinib in combination. The Kaplan-Meier method and the log-rank test determined significantly worse outcomes in relation to PFS and OS in patients with an NLR > 5 or a CRP/Alb ratio > 5. CONCLUSION: Systemic inflammation-based markers, including increases in the NLR and the CRP/Alb ratio, may be useful for predicting PC prognoses. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.subject | NEUTROPHIL-LYMPHOCYTE RATIO | - |
dc.subject | PREDICTS SURVIVAL | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | MANAGEMENT | - |
dc.subject | OUTCOMES | - |
dc.title | Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Jae Min | - |
dc.contributor.affiliatedAuthor | Lee, Hong Sik | - |
dc.contributor.affiliatedAuthor | Hyun, Jong Jin | - |
dc.identifier.doi | 10.4251/wjgo.v8.i7.555 | - |
dc.identifier.scopusid | 2-s2.0-85007385542 | - |
dc.identifier.wosid | 000408544900005 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, v.8, no.7, pp.555 - 562 | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | - |
dc.citation.title | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | - |
dc.citation.volume | 8 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 555 | - |
dc.citation.endPage | 562 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | NEUTROPHIL-LYMPHOCYTE RATIO | - |
dc.subject.keywordPlus | PREDICTS SURVIVAL | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordAuthor | Pancreatic cancer | - |
dc.subject.keywordAuthor | Neutrophil-to-lymphocyte ratio | - |
dc.subject.keywordAuthor | C-reactive protein | - |
dc.subject.keywordAuthor | Albumin | - |
dc.subject.keywordAuthor | Prognostic factor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.